On August 31, 2026, BridgeBio Pharma entered into a voluntary agreement with the U.S. government to expand Medicaid access for its medicine Attruby via the GENEROUS Model and lower drug costs for American patients. The company expects this arrangement to exclude future pricing mandates for medicines approved exclusively for orphan indications. Specific financial terms remain confidential. BridgeBio operates in the biopharmaceutical industry, developing and commercializing transformative medicines for rare genetic conditions.

BridgeBio Pharma, Inc. announced the pricing and launch of a secondary public offering of 5,000,000 shares of common stock by selling stockholder KKR Genetic Disorder L.P. The shares were priced at $78.00 per share, with an expected closing date of August 17, 2026. BridgeBio will not receive any proceeds from the sale and is not issuing new equity. The transaction aims to diversify the company's institutional shareholder base toward high-quality, long-term ownership. This filing discloses a material definitive agreement for the underwriting of these shares via William Blair & Company, Goldman Sachs & Co. LLC, and KKR Capital Markets LLC. BridgeBio Pharma operates in the biopharmaceutical industry, developing medicines for genetic conditions.

BridgeBio Pharma reported second quarter 2026 financial results showing total revenues of $243.7 million, driven by $222.4 million in U.S. Attruby net product revenue. The company closed a $1 billion preferred equity financing on July 1, 2026, and holds $720.2 million in cash as of June 30, 2026. Regulatory milestones include FDA acceptance with Priority Review for BBP-418 (PDUFA November 27, 2026), encaleret (PDUFA May 8, 2027), and the submission of an NDA for oral infigratinib. The company operates as a commercial-stage biopharmaceutical firm developing medicines for genetic conditions.

BridgeBio Pharma, Inc. announced that the FDA has accepted for filing its New Drug Application (NDA) for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1). The FDA has assigned a PDUFA target action date of May 8, 2027, and the company is preparing to launch the therapy upon approval. BridgeBio is also planning to submit a Marketing Authorization Application (MAA) to the EMA in the second half of 2026. BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing medicines for genetic conditions.

BridgeBio Pharma, Inc. entered into an Investment Agreement on July 1, 2026, to issue and sell 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock to Chinotto Investments, LLC and HCRx Investments HoldCo, L.P. for an aggregate price of $933,900,000 at $1,000 per share. The Preferred Stock is convertible into common stock at an initial conversion price of $137.79 per share and carries a 7.00% annual dividend rate. BridgeBio Pharma, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases.